Akebia Therapeutics Company Profile (NASDAQ:AKBA)

Analyst Ratings

Consensus Ratings for Akebia Therapeutics (NASDAQ:AKBA) (?)
Ratings Breakdown: 1 Hold Rating(s), 6 Buy Rating(s)
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $16.71 (91.90% upside)

Analysts' Ratings History for Akebia Therapeutics (NASDAQ:AKBA)
Show:
DateFirmActionRatingPrice TargetActions
7/12/2016Credit Suisse Group AGReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/16/2016HC WainwrightReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/8/2016Brean CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/8/2016Morgan StanleyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/16/2016Needham & Company LLCLower Price TargetBuy$18.00 -> $14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$24.00 -> $16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$24.00 -> $16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/12/2015Nomura Holdings Inc.Reiterated RatingBuy$37.00 -> $27.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/26/2014 forward)

Earnings

Earnings History for Akebia Therapeutics (NASDAQ:AKBA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/9/2016        
3/14/2016Q415($0.28)($0.66)$11.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q3($0.52)($0.68)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2015Q215($0.51)($0.40)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015($0.57)($0.53)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/4/2015Q414($0.66)($0.52)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q314($0.45)($0.47)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014($0.34)($0.39)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014($0.38)($0.04)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Akebia Therapeutics (NASDAQ:AKBA)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Akebia Therapeutics (NASDAQ:AKBA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Akebia Therapeutics (NASDAQ:AKBA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/6/2016Duane NashDirectorSell1,980$7.48$14,810.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/5/2016Nicole R. HadasSVPSell1,557$7.47$11,630.79View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/4/2016Michel DahanSVPSell1,401$9.41$13,183.41View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/2/2015Nicole R HadasSVPSell1,484$8.67$12,866.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/2/2015Nicole R HadasSVPSell1,484$9.54$14,157.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/22/2015Muneer A SatterDirectorBuy420,000$8.25$3,465,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/2/2015Nicole R HadasSVPSell1,483$9.09$13,480.47View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2015Nicole R HadasVPSell1,715$11.46$19,653.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/29/2014John P ButlerCEOBuy1,000$11.57$11,570.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/26/2014Duane NashDirectorSell11,933$11.23$134,007.59View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/22/2014John P ButlerCEOBuy1,000$11.92$11,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2014John P ButlerCEOBuy1,000$11.34$11,340.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2014Ronald C Renaud JrDirectorBuy5,000$11.92$59,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/26/2014Jason AmelloCFOBuy1,000$13.22$13,220.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014Muneer A SatterDirectorBuy5,000$13.18$65,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2014Muneer A SatterDirectorBuy5,000$13.88$69,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/21/2014Muneer A SatterDirectorBuy5,000$14.73$73,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2014Muneer A SatterDirectorBuy5,000$14.70$73,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2014Muneer A SatterDirectorBuy5,000$14.85$74,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2014Muneer A SatterDirectorBuy5,000$13.84$69,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/17/2014Muneer A SatterDirectorBuy5,000$12.94$64,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/14/2014Muneer A SatterDirectorBuy5,000$11.91$59,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2014Muneer A SatterDirectorBuy5,000$11.56$57,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2014John P ButlerCEOBuy1,000$10.31$10,310.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2014Muneer A SatterDirectorBuy5,000$11.90$59,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/25/2014A/S NovoInsiderBuy182,590$17.00$3,104,030.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/25/2014Jason AmelloCFOBuy4,000$17.00$68,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/25/2014John P ButlerCEOBuy13,850$17.00$235,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/25/2014Muneer A SatterDirectorBuy91,295$17.00$1,552,015.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Akebia Therapeutics (NASDAQ:AKBA)
DateHeadline
07/25/16 07:11 AMNew Broker Ratings For Akebia Therapeutics, Inc. (AKBA) - FTSE News
07/23/16 02:24 PMEquity Roundup: Stock Performance Focus on Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Press Telegraph
07/21/16 02:24 PMAkebia Therapeutics, Inc. (NASDAQ:AKBA): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/20/16 10:32 AMWhy Need to Watch: Invuity (NASDAQ:IVTY), Akebia Therapeutics (NASDAQ:AKBA), Taiwan Semiconductor ... - KC Register
07/19/16 02:25 PMAkebia Therapeutics Incorporated (NASDAQ:AKBA) Short Interest Increased By 0.41% - Consumer Eagle
07/18/16 02:27 PMIs $26 Price Target Attainable For Akebia Therapeutics, Inc. (NASDAQ:AKBA)? - Investor Newswire
07/17/16 07:10 AMShares Moving Down on the Week: Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Engelwood Daily
07/16/16 10:49 AMAre Analysts Bullish Akebia Therapeutics Inc (NASDAQ:AKBA) After Last Week? - Consumer Eagle
07/16/16 10:49 AMAkebia Therapeutics Inc. (AKBA) is Trading Lower on Unusual Volume for July 13 - Equities.com
07/14/16 02:26 PMOption Market: Akebia Therapeutics Inc Risk Hits An Elevated Level - CML News
07/13/16 02:26 PMAkebia Therapeutics, Inc. (NASDAQ:AKBA) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/12/16 02:28 PMActive Watch List: Akebia Therapeutics, Inc. (NASDAQ:AKBA), Cisco Systems, Inc. (NASDAQ:CSCO), IberiaBank Corp ... - KC Register
07/11/16 02:25 PMStrong Sell Calls For Akebia Therapeutics, Inc. (NASDAQ:AKBA) At 0 - Investor Newswire
07/09/16 10:31 AMAkebia Therapeutics Incorporated (NASDAQ:AKBA) Sellers Covered 4.1% of Their Shorts - Press Telegraph
07/08/16 07:36 PMAkebia Therapeutics Inc Formed a Bearish Double Bottom Pattern, Could Be One of The Worst Performers Going ... - Engelwood Daily
07/08/16 10:28 AMAkebia Therapeutics, Inc. Stock Momentum at Critical Inflection Point - CML News
07/07/16 10:20 AMStock Tracking Down This Month; Investor Alert on Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Engelwood Daily
07/07/16 10:20 AMCan Akebia Therapeutics, Inc. (NASDAQ:AKBA) Improve on the Earnings Front? - Engelwood Daily
07/07/16 10:20 AMAkebia Therapeutics Inc. (AKBA) Jumps 6.13% on July 06 - Equities.com
07/06/16 02:25 PMIncreased Volatility Watch for: Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Engelwood Daily
07/05/16 03:11 PMAkebia to Present at the Cantor Fitzgerald Annual Healthcare Conference - [at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of ...
07/04/16 02:24 PMAkebia Therapeutics, Inc. (NASDAQ:AKBA) Expected to Reach Highs Of $26 - Investor Newswire
07/04/16 07:12 AMBroker Outlook For The Week Ahead Akebia Therapeutics, Inc. (AKBA) - Fiscal Standard
06/29/16 02:23 PMAkebia Therapeutics Inc on Focus After Raising In Today's Session - Engelwood Daily
06/28/16 07:35 AMCovering the Bases on Akebia Therapeutics, Inc. (NASDAQ:AKBA): Where is the Stock Going? - Press Telegraph
06/28/16 07:35 AMStrong Sell Calls Recommendations For Akebia Therapeutics, Inc. (NASDAQ:AKBA) At 0 - Investor Newswire
06/26/16 02:22 PMAkebia Therapeutics, Inc. (AKBA) Broker Price Targets For The Coming Week - Fiscal Standard
06/25/16 02:25 PMAkebia Therapeutics Incorporated (NASDAQ:AKBA) Sellers Covered 4.1% of Their Shorts - Engelwood Daily
06/24/16 02:22 PMShare Volatility Check for: Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Press Telegraph
06/24/16 09:46 AMAkebia Therapeutics Inc. (AKBA) Jumps 6.28% on June 23 - Equities.com
06/23/16 10:13 AMAkebia Therapeutics Inc. (AKBA) is Trading Lower on Unusual Volume for June 21 - Equities.com
06/21/16 03:07 PMAKEBIA THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/21/16 07:12 AMStrong Buy Calls Count For Akebia Therapeutics, Inc. (NASDAQ:AKBA) At 3 - Investor Newswire
06/21/16 07:12 AMAkebia Therapeutics, Inc. (AKBA) Current Analyst Ratings - Fiscal Standard
06/13/16 02:22 PMTrend Of Rating Given To Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Investor Newswire
06/10/16 10:49 AMAkebia Therapeutics, Inc. (NASDAQ:AKBA) Earnings Preview: Should Investors Be Nervous? - iStreetWire
06/08/16 10:53 AMAkebia Therapeutics, Inc. (AKBA) Updated Price Targets - FTSE News
06/03/16 10:52 AMAkebia Therapeutics Inc (NASDAQ:AKBA) Given Average Recommendation of “Buy” from Analysts - Let Me Know About This
06/03/16 10:52 AMBroker Watchlist: Akebia Therapeutics, Inc. (AKBA) - Share Trading News
06/02/16 12:01 PMAkebia Therapeutics, Inc. :AKBA-US: Earnings Analysis: Q1, 2016 By the Numbers : June 2, 2016 -
06/01/16 10:47 AMAkebia Therapeutics Incorporated (NASDAQ:AKBA) Shorted Shares Increased 0.12% After Market Selling - HNN - Akebia Therapeutics Incorporated (NASDAQ:AKBA) Shorted Shares Increased 0.12% After Market SellingHNNThe short interest to Akebia Therapeutics Incorporated's float is 16.35%. The stock increased 1.25% or $0.11 during the last trading session, hitting $8.91. Akebia Therapeutics Inc (NASDAQ:AKBA) has declined 2.09% since October 23, 2015 and is ...
05/30/16 09:19 PMBrean Capital Reiterates Buy Rating for Akebia Therapeutics Inc (AKBA) - Let Me Know About This - Brean Capital Reiterates Buy Rating for Akebia Therapeutics Inc (AKBA)Let Me Know About ThisAkebia Therapeutics logo Akebia Therapeutics Inc (NASDAQ:AKBA)'s stock had its “buy” rating reissued by equities research analysts at Brean Capital in a report released on Sunday. A number of other equities research analysts also recently commented on ...
05/30/16 09:19 PMBrean Capital Reiterates Buy Rating for Akebia Therapeutics Inc (AKBA) - Let Me Know About This - Brean Capital Reiterates Buy Rating for Akebia Therapeutics Inc (AKBA)Let Me Know About ThisAkebia Therapeutics logo Akebia Therapeutics Inc (NASDAQ:AKBA)'s stock had its “buy” rating reissued by equities research analysts at Brean Capital in a report released on Sunday. A number of other equities research analysts also recently commented on ...
05/23/16 12:12 PMAkebia Therapeutics (AKBA) Announces Positive Data from Vadadustat Drug-Interaction Study in CKD - StreetInsider.com - Akebia Therapeutics (AKBA) Announces Positive Data from Vadadustat Drug-Interaction Study in CKDStreetInsider.comAkebia Therapeutics, Inc. (Nasdaq: AKBA) presented positive results from a drug-drug interaction study of vadadustat, the Company's oral therapy for the treatment of anemia related to chronic kidney disease (CKD). The study demonstrated that vadadustat ...and more »
05/23/16 06:01 AM7:01 am Akebia Therapeutics announces 'positive' results from a drug-drug interaction study of vadadustat -
05/23/16 06:00 AMAkebia Announces Positive Vadadustat Data Demonstrating No Clinically Significant Drug-Drug Interaction - [Business Wire] - Akebia Therapeutics, Inc. , a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor , today presented positive results from a drug-drug interaction study of vadadustat, the Company’s oral therapy for the treatment of anemia related to chronic kidney disease .
05/19/16 12:06 AMRevenue Update on Akebia Therapeutics Inc(NASDAQ:AKBA) - Trade Calls - Revenue Update on Akebia Therapeutics Inc(NASDAQ:AKBA)Trade CallsAkebia Therapeutics Inc(NASDAQ:AKBA) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 5, 2016. Company reported revenue of $0.00. Analysts estimated a revenue of $12.38M. Earnings per ...
05/17/16 06:41 PMAkebia Therapeutics Inc (AKBA) Jumps 5.91% on May 16 - Equities.com - Akebia Therapeutics Inc (AKBA) Jumps 5.91% on May 16Equities.comAkebia Therapeutics Inc (AKBA) was among the biggest gainers on the Russell 2000 for Monday May 16 as the stock popped 5.91% to $8.24, representing a gain of $0.46 per share. Some 185,466 shares traded hands on 1,483 trades, compared with an ...
05/16/16 11:48 PMAkebia Therapeutics, Inc. (AKBA) Broker Price Targets For The Coming Week - Share Trading News - Akebia Therapeutics, Inc. (AKBA) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Akebia Therapeutics, Inc. (AKBA). The latest reports which are currently in issue on Sunday 15th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, ...and more »
05/16/16 06:32 AMAkebia to Present at the 2016 UBS Global Healthcare Conference - [at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients through the biology of hypoxia-inducible ...

Social

About Akebia Therapeutics

Akebia Therapeutics logoAkebia Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutics based on hypoxia inducible factor (HIF) biology, and the commercialization of these products for patients with serious medical needs. The Company's segment is the business of developing and commercializing proprietary therapeutics based on HIF biology. The Company is involved in developing its lead product candidate, vadadustat, as an oral therapy for the treatment of anemia in chronic kidney disease (CKD) subjects not on dialysis and in subjects on dialysis. Its other clinical candidate, AKB-6899, is designed as a small molecule HIF prolyl-hydroxylase (HIF-PH) inhibitor with therapeutic benefit in oncology and ophthalmology. The Company is engaged in conducting approximately two global Phase III studies for the treatment of anemia in non-dialysis dependent patients, and over two Phase III studies for the treatment of anemia in dialysis-dependent CKD patients.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AKBA
  • CUSIP:
Key Metrics:
  • Previous Close: $8.57
  • 50 Day Moving Average: $8.18
  • 200 Day Moving Average: $8.37
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $157.56M
  • Beta: 0.58
  • Current Year EPS Consensus Estimate: $-2.54 EPS
  • Next Year EPS Consensus Estimate: $-3.10 EPS
Additional Links:
Akebia Therapeutics (NASDAQ:AKBA) Chart for Tuesday, July, 26, 2016